Anti-SL9A4/ SLC9A4/ NHE4 monoclonal antibody

Anti-SL9A4/ SLC9A4/ NHE4 antibody for FACS & in-vivo assay

Target products collectionGo to SLC9A4/SLC9A4 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1672-Ab-1/ GM-Tg-hg-MP1672-Ab-2Anti-Human SLC9A4 monoclonal antibodyHuman
GM-Tg-rg-MP1672-Ab-1/ GM-Tg-rg-MP1672-Ab-2Anti-Rat SLC9A4 monoclonal antibodyRat
GM-Tg-mg-MP1672-Ab-1/ GM-Tg-mg-MP1672-Ab-2Anti-Mouse SLC9A4 monoclonal antibodyMouse
GM-Tg-cynog-MP1672-Ab-1/ GM-Tg-cynog-MP1672-Ab-2Anti-Cynomolgus/ Rhesus macaque SLC9A4 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1672-Ab-1/ GM-Tg-felg-MP1672-Ab-2Anti-Feline SLC9A4 monoclonal antibodyFeline
GM-Tg-cang-MP1672-Ab-1/ GM-Tg-cang-MP1672-Ab-2Anti-Canine SLC9A4 monoclonal antibodyCanine
GM-Tg-bovg-MP1672-Ab-1/ GM-Tg-bovg-MP1672-Ab-2Anti-Bovine SLC9A4 monoclonal antibodyBovine
GM-Tg-equg-MP1672-Ab-1/ GM-Tg-equg-MP1672-Ab-2Anti-Equine SLC9A4 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1672-Ab-1/ GM-Tg-hg-MP1672-Ab-2; GM-Tg-rg-MP1672-Ab-1/ GM-Tg-rg-MP1672-Ab-2;
GM-Tg-mg-MP1672-Ab-1/ GM-Tg-mg-MP1672-Ab-2; GM-Tg-cynog-MP1672-Ab-1/ GM-Tg-cynog-MP1672-Ab-2;
GM-Tg-felg-MP1672-Ab-1/ GM-Tg-felg-MP1672-Ab-2; GM-Tg-cang-MP1672-Ab-1/ GM-Tg-cang-MP1672-Ab-2;
GM-Tg-bovg-MP1672-Ab-1/ GM-Tg-bovg-MP1672-Ab-2; GM-Tg-equg-MP1672-Ab-1/ GM-Tg-equg-MP1672-Ab-2
Products NameAnti-SLC9A4 monoclonal antibody
Formatmab
Target NameSLC9A4
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-SLC9A4 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species SL9A4/ SLC9A4/ NHE4 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1672
    Target NameSLC9A4
    Gene ID389015,110895,24785,712136,100682768,101101634,536970,100058138
    Gene Symbol and SynonymsD730009J23Rik,NHE4,SLC9A4
    Uniprot AccessionQ6AI14,P26434
    Uniprot Entry NameSL9A4_HUMAN,SL9A4_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000180251
    Target ClassificationN/A

    The target: SLC9A4, gene name: SLC9A4, also named as NHE4. Predicted to enable potassium:proton antiporter activity and sodium:proton antiporter activity. Predicted to be involved in potassium ion transmembrane transport; regulation of intracellular pH; and sodium ion import across plasma membrane. Predicted to act upstream of or within epithelial cell development and gastric acid secretion. Predicted to be located in several cellular components, including apical plasma membrane; basolateral plasma membrane; and vacuolar membrane. Predicted to be integral component of membrane. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.